Close

Form 8-K/A LIGAND PHARMACEUTICALS For: Jan 08

March 22, 2016 5:25 PM EDT

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K/A

Amendment No. 1

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 8, 2016

 

 

LIGAND PHARMACEUTICALS INCORPORATED

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-33093   77-0160744

(State or other jurisdiction of

incorporation or organization)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

11119 North Torrey Pines Road, Suite 200

La Jolla, CA

  92037
(Address of principal executive offices)   (Zip Code)

(858) 550-7500

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Explanatory Note

This Amendment No. 1 (this “Amendment”) is being filed by Ligand Pharmaceuticals Incorporated (“Ligand”) to provide the financial statements that were previously omitted from the Current Report on Form 8-K filed on January 8, 2016 (the “Original Report”), relating to the acquisition of Open Monoclonal Technology, Inc. by way of a merger.

The sole purpose of this Amendment is to provide the financial statements and pro forma information required by Item 9.01, which were excluded from the Original Report.

 

Item 9.01. Financial Statements and Exhibits.

 

  (a) Financial Statements of Businesses Acquired

The audited combined financial statements of Open Monoclonal Technology, Inc., OMT Therapeutics, Inc. and OMT, LLC. as of and for the year ended December 31, 2015, are filed as Exhibit 99.1 to this Amendment and are included herein by reference.

 

  (b) Pro Forma Financial Information

The unaudited pro forma condensed combined financial statements as of and for the year ended December 31, 2015, after giving effect to the acquisition of Open Monoclonal Technology, Inc., are filed as Exhibit 99.2 to this Amendment and are included herein by reference.

 

  (d) Exhibits

 

Exhibit

No.

  

Description

  2.1    Consent of Frank, Rimerman + Co. LLP independent registered public accounting firm of Open Monoclonal Technology, Inc.
99.1    Audited combined financial statements of Open Monoclonal Technology, Inc., OMT Therapeutics, Inc and OMT, LLC. as of and for the year ended December 31, 2015
99.2    Unaudited pro forma condensed combined financial information


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    LIGAND PHARMACEUTICALS INCORPORATED
Date: March 22, 2016     By:  

/s/ Charles Berkman

    Name:   Charles Berkman
    Title:   Vice President, General Counsel and Secretary

Exhibit 2.1

Consent of Independent Registered Public Accounting Firm

We have issued our report dated March 18, 2016, with respect to the combined financial statements of Open Monoclonal Technology, Inc., OMT Therapeutics, Inc. and OMT, LLC included in this Current Report of Ligand Pharmaceuticals Incorporated on Form 8-K/A for the year ended December 31, 2015. We hereby consent to the incorporation by reference of said report in the Registration Statements of Ligand Pharmaceuticals Incorporated on Forms S-3 (File No. 333-208919 and File No. 333-191523) and on Forms S-8 (File No. 333-182547, File No. 333-160132 and File No. 333-131029).

 

/s/ Frank, Rimerman + Co. LLP

Palo Alto, California

March 22, 2016

Exhibit 99.1

 

 

 

Open Monoclonal Technology, Inc.,

 

OMT Therapeutics, Inc.

 

and

 

OMT, LLC

 

Combined Financial Statements

 

December 31, 2015

 


Board of Directors

Open Monoclonal Technology, Inc.,

  OMT Therapeutics, Inc. and OMT, LLC

Palo Alto, California

INDEPENDENT AUDITORS’ REPORT

Report on Combined Financial Statements

We have audited the accompanying combined financial statements of Open Monoclonal Technology, Inc. (a Delaware Corporation), OMT Therapeutics, Inc. (a Delaware Corporation), and OMT, LLC (a Delaware Limited Liability Company) (collectively OMT) (the Company), which comprise the combined balance sheet as of December 31, 2015, and the related combined statement of operation, stockholders’ equity and cash flows for the year then ended, and the related notes to the combined financial statements.

Management’s Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these combined financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of combined financial statements that are free from material misstatement, whether due to fraud or error.

Auditors’ Responsibility

Our responsibility is to express an opinion on these combined financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the combined financial statements are free from material misstatement.


An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the combined financial statements. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the combined financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity’s preparation and fair presentation of the combined financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the combined financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the combined financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2015, and the results of its operations and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Other Matter

As discussed in Note 1 to the combined financial statements, Open Monoclonal Technology, Inc. and OMT, LLC were acquired by Ligand Pharmaceuticals, Inc. Our opinion is not modified with respect to that matter.

 

LOGO

Palo Alto, California

March 18, 2016


Open Monoclonal Technology, Inc.,

OMT Therapeutics, Inc. and OMT, LLC

Combined Balance Sheet

December 31, 2015

 

 

ASSETS

  

Current Assets

 

Cash and cash equivalents

   $ 4,638,239     

Accounts receivable

    2,380     

Income tax receivable

    378,610     

Prepaid expenses and other current assets

    138,412     

Deferred income tax assets

    289,600     
 

 

 

 

Total current assets

    5,447,241     

Property and Equipment, net

    509,437     

Intangible Assets, net

    214,236     

Deposits

    66,946     

Deferred Income Tax Assets, non-current portion

    2,857,800     
 

 

 

 
   $           9,095,660     
 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

  

Current Liabilities

 

Accounts payable

   $ 505,633     

Accrued expenses and other current liabilities

    639,846     

Deferred revenue

    1,979,167     
 

 

 

 

Total current liabilities

    3,124,646     

Preferred Stock Warrant Liability

    545,053     

Commitments and Contingencies (Notes 9 and 10)

 

Stockholders’ Equity

 

Series B, convertible preferred stock

    4,590     

Series A, convertible preferred stock

    4,363     

Common stock

    5,302     

Additional paid-in capital

    9,405,254     

Accumulated deficit

    (3,993,548)    
 

 

 

 

Total stockholders’ equity

    5,425,961     
 

 

 

 

Total liabilities and stockholders’ equity

   $ 9,095,660     
 

 

 

 

 

See Independent Auditors’ Report and Notes to Combined Financial Statements

- 3 -


Open Monoclonal Technology, Inc.,

OMT Therapeutics, Inc. and OMT, LLC

Combined Statement of Operation

Year ended December 31, 2015

 

 

Revenues

    $         7,524,654     

Cost of Revenue

     194,734     
  

 

 

 
     7,329,920     

Operating Expenses

  

Sales and marketing

     556,412     

General and administrative

     3,360,477     

Research and development

     6,093,852     
  

 

 

 

Total operating expenses

     10,010,741     
  

 

 

 

Loss from Operations

     (2,680,821)    

Other Income (Expense)

  

Interest expense

     (257,827)    

Gain on revaluation of warrants

     47,804     

Other income

     381     

Foreign currency translation loss

     (48,840)    
  

 

 

 
     (258,482)    
  

 

 

 

Loss from Operations before Income and Foreign Tax Benefit

     (2,939,303)    

Income and Foreign Tax Benefit

     1,273,998     
  

 

 

 

Net Loss

    $ (1,665,305)    
  

 

 

 

 

See Independent Auditors’ Report and Notes to Combined Financial Statements

- 4 -


Open Monoclonal Technology, Inc.,

OMT Therapeutics, Inc. and OMT, LLC

Combined Statement of Stockholders’ Equity

Year Ended December 31, 2015

 

 

    Convertible Preferred Stock     Common Stock     Common Units                    
    Open

 

Monoclonal

 

Technology, Inc.

 

Shares

    OMT

 

Therapeutics, Inc.

 

Shares

    OMT, LLC

 

Shares

    Amount     Open

 

Monoclonal

 

Technology, Inc.

 

Shares

    OMT

 

Therapeutics, Inc.

 

Shares

    Amount     OMT, LLC

 

Shares

    Amount     Additional

 

Paid-in

 

Capital

    Retained

 

Earnings

 

(Accumulated

 

Deficit)

    Total  

Balances, December 31, 2014

    8,952,748          50,000          4,562,599         $   8,953          4,982,342          8,882,492         $ 4,982          4,585,065         $ -         $ 9,165,580         $ 1,457,150         $ 10,636,665     

Issuance of common stock upon exercise of stock options

    -          -          -          -          275,000          446,622          320          -          -          187,077          -          187,397     

Unvested portion of early exercised stock options

    -          -          -          -          -          -          -          -          -          (101,461)         -          (101,461)    

Vesting of early exercised stock options

    -          -          -          -          -          -          -          -          -          28,109          -          28,109     

Stock-based compensation

    -          -          -          -          -          -          -          -          -          125,949          -          125,949     

Distributions to members

    -          -          -          -          -          -          -          -          -          -          (3,785,393)         (3,785,393)    

Net loss

    -          -          -          -          -          -          -          -          -          -          (1,665,305)           (1,665,305)    
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Balances, December 31, 2015

    8,952,748          50,000          4,562,599         $ 8,953          5,257,342          9,329,114         $   5,302          4,585,065         $   -         $   9,405,254         $   (3,993,548)        $ 5,425,961     
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

See Independent Auditors’ Report and Notes to Combined Financial Statements

- 5 -


Open Monoclonal Technology, Inc.,

OMT Therapeutics, Inc. and OMT, LLC

Combined Statement of Cash Flows

Year Ended December 31, 2015

 

 

Cash Flows from Operating Activities

  

Net loss

    $ (1,665,305)    

Adjustments to reconcile net loss to net cash provided by operating activities:

  

Depreciation and amortization

                 193,093     

Non-cash interest expense related to convertible notes payable discounts

     131,146     

Revaluation of preferred stock warrant liability

     (47,804)    

Stock-based compensation

     125,949     

Changes in operating assets and liabilities:

  

Escrow receivable

     4,350,000     

Accounts receivable

     17,626     

Prepaid expenses and other current assets

     898,548     

Income tax receivable

     679,583     

Deferred income tax assets

     (1,192,600)    

Accounts payable

     (624,623)    

Accrued expenses and other current liabilities

     349,726     

Deferred revenue

     (500,000)    
  

 

 

 

Net cash provided by operating activities

     2,715,339     

Cash Flows from Investing Activities

  

Purchase of property and equipment

     (536,113)    

Purchase of intangible assets

     (124,739)    

Increase in deposits

     (51,955)    
  

 

 

 

Net cash used in operating activities

     (712,807)    

Cash Flows from Financing Activities

  

Repayment of convertible note payable

     (3,999,500)    

Distribution to members

     (3,785,393)    

Proceeds from exercise of common stock options

     187,397     
  

 

 

 

Net cash used in investing activities

     (7,597,496)    
  

 

 

 

Net Decrease in Cash and Cash Equivalents

     (5,594,964)    

Cash and Cash Equivalents, December 31, 2014

     10,233,203     
  

 

 

 

Cash and Cash Equivalents, December 31, 2015

    $ 4,638,239     
  

 

 

 

 

(continued)

- 6 -


Open Monoclonal Technology, Inc.,

OMT Therapeutics, Inc. and OMT, LLC

Combined Statement of Cash Flows (continued)

Year Ended December 31, 2015

 

 

Supplemental Disclosure of Cash Flow Information

  

Cash paid for interest

    $             681,343     
  

 

 

 

Cash paid for income taxes

    $ 36,456     
  

 

 

 

Supplemental Schedule of Non-Cash Financing Activities

  

Vesting of early exercised stock options

    $ 28,109     
  

 

 

 

Early exercise of stock options

    $ 101,461     
  

 

 

 

 

See Independent Auditors’ Report and Notes to Combined Financial Statements

- 7 -


Open Monoclonal Technology, Inc.,

OMT Therapeutics, Inc. and OMT, LLC

Notes to Combined Financial Statements

 

 

1.

Nature of Business

Open Monoclonal Technology, Inc. (OMTI) was incorporated in the state of Delaware on May 22, 2007. OMTI was founded to invent and commercialize a human monoclonal antibody platform based on rats. OMTI generates revenue from licensing its drug development platform domestically and internationally direct to bio-pharmaceutical companies, as well as through contract research organizations.

OMT Therapeutics, Inc. (OMTT) was incorporated in the state of Delaware on August 9, 2009 as HCO Antibody, Inc. and subsequently changed its name to OMT Therapeutics, Inc. OMTT was founded to develop next-generation therapies for the treatment of cancer, antibiotic-resistant bacteria, and emerging viruses.

OMT, LLC (OMT, LLC) was incorporated in the state of Delaware on March 3, 2010. OMT, LLC was founded to be the holding company for three spin-offs from OMTI: OMT1, Inc., OMT2, Inc., and OMT3, Inc. OMT3, Inc. was sold in 2013.

On January 8, 2016, OMTI and OMT, LLC were acquired by Ligand Pharmaceuticals, Inc.

 

2.

Significant Accounting Policies

Basis of Presentation and Principles of Combination:

The Company applies the provisions set forth in the Financial Accounting Standard Board (FASB) amended Variable Interest Entities (VIE) sub-section of Accounting Standards Codification (ASC) 810, Consolidation. ASC 810 requires formal assessment at each reporting period regarding which party within the VIE is considered the primary beneficiary and also requires a number of disclosures related to VIEs. A qualitative approach is required for identifying the primary beneficiary of a VIE based on the power to direct activities that most significantly impact the economic performance of the entity and the obligation to absorb losses or right to receive benefits that could be significant.

OMTI determined OMTT and OMT, LLC are under common control and do not have sufficient capital to fund their own activities. Therefore, OMTT and OMT, LLC are considered a VIE, with OMTI being the primary beneficiary.

The accompanying combined financial statements include the accounts of OMTI, OMTT and OMT, LLC (collectively OMT).

 

- 8 -


Open Monoclonal Technology, Inc.,

OMT Therapeutics, Inc. and OMT, LLC

Notes to Combined Financial Statements

 

 

2.

Significant Accounting Policies (continued)

 

Basis of Presentation and Principles of Combination: (continued)

 

The accounts of OMTT are comprised of OMTT and its wholly-owned subsidiary, Recombinant Antibody Technologies Ltd. (RAT). The accounts of OMT, LLC include the consolidation of OMT 1, Inc. and OMT 2, Inc. All significant inter-company accounts and transactions have been eliminated.

Foreign Currency Translation:

The functional currency for the Company and its combined entities is the United States dollar. All assets and liabilities denominated in foreign currencies are translated using exchange rates in effect at the balance sheet date. Revenue and expenses are translated using the average exchange rate for the reporting period. Foreign currency transaction gains and losses are recorded in the combined statement of operations.

Revenue Recognition:

Revenue consists of license fees and milestone payments. Non-refundable fees where the Company has no continuing performance obligations are recognized as revenues when there is persuasive evidence of an arrangement and collection is reasonably assured. In situations where the Company has continuing performance obligations, non-refundable fees are deferred and are recognized ratably over the projected performance period. The Company recognizes milestone payments, which are typically related to specific targets requested by customers and other achievements reached by the Company, as revenues when the milestone is accomplished and collection is reasonably assured.

Other nonrefundable, up-front license fees and milestone payments with standalone value that are not dependent on any future performance by the Company under the agreements are recognized as revenue upon the earlier of when payments are received or collection is assured. In contrast, such fees and payments are deferred if the Company has continuing performance obligations. Amounts received under multiple-element arrangements requiring ongoing services or performance are recognized over the period of such services or performance.

 

- 9 -


Open Monoclonal Technology, Inc.,

OMT Therapeutics, Inc. and OMT, LLC

Notes to Combined Financial Statements

 

 

2.

Significant Accounting Policies (continued)

 

Revenue Recognition: (continued)

 

Sales-based milestone revenue is accounted for similarly to royalties, with revenue recognized upon achievement of the milestone assuming all other revenue recognition criteria for milestones are met. Revenue from development and regulatory milestones is recognized when earned, as evidenced by written acknowledgement from the customer, provided that (i) the milestone event is substantive, its achievability was not reasonably assured at the inception of the agreement, and the Company has no further performance obligations relating to that event, and (ii) collectability is reasonably assured. If these criteria are not met, the milestone payment is recognized over the remaining period of the performance obligations under the arrangement.

Deferred Revenue:

Deferred revenue consists of billings or payments received in advance of revenue recognition from the Company’s contract revenues, as described above, and is recognized as revenue when all of the revenue recognition criteria are met. The portion of deferred revenue that the Company anticipates will be recognized in the next 12 month-period is recorded as current deferred revenue.

Research and Development Costs:

Research and development costs are expensed as incurred.

Cash and Cash Equivalents:

Cash and cash equivalents include all cash balances and highly liquid investments purchased with a maturity of three months or less.

Concentration of Credit Risk:

Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash and cash equivalents at one domestic financial institution. The Company is exposed to credit risk in the event of default by the financial institutions to the extent that cash and cash equivalents are in excess of the amount insured by the Federal Deposit Insurance Corporation (FDIC). The Company has not experienced any losses on its cash deposits since inception. At December 31, 2015, the Company had cash and cash equivalents of $415,195 at one foreign financial institution, which is not insured by the FDIC.

 

- 10 -


Open Monoclonal Technology, Inc.,

OMT Therapeutics, Inc. and OMT, LLC

Notes to Combined Financial Statements

 

 

2.

Significant Accounting Policies (continued)

 

Major Customers:

Major customers are defined as customers who represent greater than 10% of the Company’s annual revenue. The Company had four major customers who accounted for 63% of total revenue during 2015. There were no accounts receivable due from these four major customers at December 31, 2015. The Company does not believe it is dependent on any one customer in the long-term.

Use of Estimates:

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of revenue and expenses in the combined financial statements and accompanying notes. Estimates are used in accounting for, among other things, useful lives of property and equipment and intangible assets, impairment of long-lived assets, certain accrued expenses, valuation allowance for deferred income tax assets and the fair value of warrants and of options granted under the Company’s stock-based compensation plans. Actual results could differ from those estimates.

Property and Equipment:

Property and equipment are stated at cost, net of accumulated depreciation. The Company depreciates property and equipment using the straight-line method over their estimated useful lives, generally five years for equipment and two years for computer hardware and software.

Stock-Based Compensation:

The Company generally grants stock options to its employees for a fixed number of shares with an exercise price equal to the fair value of the shares at the date of grant. The Company accounts for employee options using the fair value method and all stock-based compensation is recognized over the grantee’s service period.

Stock-based compensation for options or warrants granted to non-employees is measured on the date of performance at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. Stock-based compensation for options granted to non-employees is periodically re-measured as the underlying options vest.

 

- 11 -


Open Monoclonal Technology, Inc.,

OMT Therapeutics, Inc. and OMT, LLC

Notes to Combined Financial Statements

 

 

2.

Significant Accounting Policies (continued)

 

Accounting for Impairment of Long-Lived Assets:

The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets held and used is measured by comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. No asset impairment was recorded in 2015.

Risks and Uncertainties:

The Company is subject to a number of risks associated with companies at a similar stage, including dependence on key individuals, competition from substitute services and larger companies, volatility of the industry, ability to obtain adequate financing to support growth, the ability to attract and retain additional qualified personnel to manage the anticipated growth of the Company and general economic conditions.

Preferred Stock Warrant Liability:

The Company accounts for outstanding warrants to purchase shares of the Company’s convertible preferred stock in accordance with FASB ASC Topic 480, Distinguishing Liabilities from Equity. Under ASC 480, the Company is required to classify certain warrants to purchase shares of stock as liabilities and adjust the warrant instruments to fair value at each reporting period.

Fair Value Measurements:

The Company uses a three-level hierarchy for fair value measurements based on the nature of inputs used in the valuation of an asset or liability as of the measurement date. The three-level hierarchy prioritizes, within the measurement of fair value, the use of market-based information over entity-specific information. Fair value focuses on an exit price and is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The inputs or methodology used for valuing financial instruments are not necessarily an indication of the risk associated with investing in those instruments.

 

- 12 -


Open Monoclonal Technology, Inc.,

OMT Therapeutics, Inc. and OMT, LLC

Notes to Combined Financial Statements

 

 

2.

Significant Accounting Policies (continued)

 

Fair Value Measurements: (continued)

 

The three-level hierarchy for fair value measurements is defined as follows:

 

Level I   

Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level II   

Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

Level III   

Inputs to the valuation methodology, which are significant to the fair value measurement, are unobservable.

An investment’s categorization within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement.

The Company’s preferred stock warrant liability has been classified within Level III of the fair value hierarchy at December 31, 2015. The changes in the fair value of the preferred stock warrant liability are summarized below.

 

Fair value at December 31, 2014

   $         592,857   

Revaluation of warrants

     (47,804)   
  

 

 

 

Fair value at December 31, 2015

   $ 545,053   
  

 

 

 

Income Taxes:

The Company accounts for income taxes using the asset and liability method. Under this method, deferred income tax assets and liabilities are recorded based on the estimated future tax effects of differences between the financial statement and income tax basis of existing assets and liabilities. Deferred income taxes are classified as current or non-current, based on the classifications of the related assets and liabilities giving rise to the temporary differences. A valuation allowance is provided against the Company’s deferred income tax assets when their realization is not reasonably assured.

 

- 13 -


Open Monoclonal Technology, Inc.,

OMT Therapeutics, Inc. and OMT, LLC

Notes to Combined Financial Statements

 

 

2.

Significant Accounting Policies (continued)

 

Recent Accounting Pronouncement not yet Effective:

In May 2014, the Financial Account Standards Board (FASB) issued Accounting Standard Codification (ASC) Topic 606, Revenue from Contracts with Customers. This accounting standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers to reflect the consideration to which the entity expects to be entitled to in exchange for goods and services.

The standard will replace most existing revenue recognition guidance accounting principles generally accepted in the United States of America. Topic 606 is effective for the Company as of January 1, 2019, and permits the use of either a retrospective or cumulative effect transition method. The Company has not selected a transition method and is currently evaluating the effect Topic 606 will have on its consolidated financial statements and related disclosures.

In February 2016, the FASB issued ASU 2016-02, Leases. This standard requires all entities that lease assets with terms of more than 12 months to capitalize the assets and related liabilities on the balance sheet.

The Standard is effective for the Company as of January 1, 2020 and requires the use of a modified retrospective transition approach for its adoption. The Company is currently evaluating the effect ASU 2016-02 will have on its consolidated financial statements and related disclosures. Management expects the assets leased under operating leases and disclosed in Note 5 to the consolidated financial statements will be capitalized together with the related lease obligations on the balance sheet upon the adoption of ASU 2016-02.

 

3.

Property and Equipment

Property and equipment consists of the following at December 31, 2015:

 

Machinery and equipment

   $         495,982   

Computer equipment and software

     40,131   
  

 

 

 
     536,113   

Less accumulated depreciation

     (26,676
  

 

 

 
   $         509,437   
  

 

 

 

 

- 14 -


Open Monoclonal Technology, Inc.,

OMT Therapeutics, Inc. and OMT, LLC

Notes to Combined Financial Statements

 

 

4.

Intangible Assets

Intangible assets consist of patents with a cost basis of $1,027,554 net of accumulated amortization of $813,318 at December 31, 2015. Estimated future amortization expense for intangible assets at December 31, 2015 is as follows:

 

Years ending December 31:

  

2016

   $         125,000   

2017

     66,000   

2018

     23,000   
  

 

 

 
   $         214,000   
  

 

 

 

 

5.

Convertible Note Payable

In May 2013, OMTI entered into a $4,999,500 convertible promissory note agreement. The note bore interest at the rate of 8% per annum and matured in May 2016 with an option to convert into convertible preferred stock of OMTI or any of their affiliates. The convertible promissory note agreement allowed OMTI to prepay up to $1,000,000 of the principal amount without penalty on or prior to December 31, 2013. In October 2013, OMTI paid back $1,000,000. In June 2015, OMTI paid back the outstanding principal and accrued interest in full of $3,999,500 and $681,343, respectively.

 

- 15 -


Open Monoclonal Technology, Inc.,

OMT Therapeutics, Inc. and OMT, LLC

Notes to Combined Financial Statements

 

 

6.

Income Taxes

OMTI:

OMTI applies the provisions set forth in Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 740 to account for uncertainty in income taxes. In the preparation of income tax returns in federal and state jurisdictions, OMTI asserts certain income tax positions based on its understanding and interpretation of income tax laws. The taxing authorities may challenge such positions, and the resolution of such matters could result in recognition of income tax expense in OMTI’s financial statements. Management believes it has used reasonable judgments and conclusions in the preparation of its income tax returns.

OMTI uses the “more likely than not” criterion for recognizing the income tax benefit of uncertain income tax positions and establishing measurement criteria for income tax benefits. OMTI has evaluated the impact of these positions and believes that its income tax filing positions and deductions will be sustained upon examination. Accordingly, no reserves for uncertain income tax positions or related accruals for interest and penalties have been recorded as of December 31, 2015. In the event OMTI should need to recognize interest and penalties related to unrecognized income tax liabilities, this amount will be recorded as an accrued liability and an increase to income tax expense.

 

- 16 -


Open Monoclonal Technology, Inc.,

OMT Therapeutics, Inc. and OMT, LLC

Notes to Combined Financial Statements

 

 

6.

Income Taxes (continued)

 

OMTI: (continued)

 

The provision for income taxes in 2015 consists of the following:

 

Current

  

Federal

   $ 84,200   

State

     800   
  

 

 

 
     85,000   

Deferred

  

Federal

     (1,078,100

State

     (197,900
  

 

 

 
     (1,276,000
  

 

 

 
   $       (1,191,000
  

 

 

 

Significant components of OMTI’s deferred income taxes are as follows at December 31, 2015:

 

Research and development credit carryforwards

   $ 820,396   

Net operating loss carryforwards

     1,854,447   

Property, equipment and intangibles tax basis differences

     141,892   

Deferred revenue

     788,389   

Stock based compensation

     41,043   

Prepaid expenses

     (498,767
  

 

 

 

Net deferred income tax assets

   $       3,147,400   
  

 

 

 

At December 31, 2015, OMTI had federal and state net operating loss carryforwards of approximately $4,608,000 and $4,933,000, respectively available to offset future tax liabilities. OMTI’s federal and state net operating losses begin to expire in 2021. OMTI has federal and state research and development income tax credits of approximately $332,000 and $488,000, respectively, at December 31, 2015. The federal income tax credits may be carried forward until 2034. The state income tax credits may be carried forward indefinitely.

 

- 17 -


Open Monoclonal Technology, Inc.,

OMT Therapeutics, Inc. and OMT, LLC

Notes to Combined Financial Statements

 

 

6.

Income Taxes (continued)

 

OMTI: (continued)

 

In evaluating its ability to recover its deferred income tax assets, OMTI considers all available positive and negative evidence including its past operating results, the existence of cumulative losses, and its forecast of future taxable income. In determining future taxable income, OMTI is responsible for assumptions utilized including the amount of federal and state pre-tax operating income, the reversal of temporary differences, and the implementation of feasible and prudent tax planning strategies. These assumptions require significant judgment about the forecasts of future taxable income and are consistent with the plans and estimates OMTI is using to manage the underlying businesses.

OMTI establishes a valuation allowance when necessary to reduce deferred income tax assets to the amounts it believes are more likely than not to be recovered. OMTI evaluates the need to retain all or a portion of the valuation allowance on deferred income tax assets. OMTI determined that it was more likely than not that OMTI would realize the majority of the deferred income tax assets. In making this determination, OMTI analyzed, among other things, recent history of earnings and cash flows, forecasts of future earnings, the nature and timing of future deductions and benefits represented by the deferred tax assets and cumulative earnings for the preceding three years. As of December 31, 2015, OMTI concluded that it was more likely than not that it would realize the majority of its deferred tax assets; therefore, no valuation allowance was deemed necessary.

OMTI files income tax returns in the U.S. federal jurisdiction and the state of California. Management believes OMTI is no longer subject to income tax examinations by taxing authorities for income tax filings prior to 2012 for federal and 2011 for state tax returns.

Section 382 of the Internal Revenue Code limits the use of net operating losses in certain situations where changes occur in ownership of a Company. If OMTI should have an ownership change of more than 50% of the value of OMTI’s net assets, utilization of the carryforwards could be restricted.

 

- 18 -


Open Monoclonal Technology, Inc.,

OMT Therapeutics, Inc. and OMT, LLC

Notes to Combined Financial Statements

 

 

6.

Income Taxes (continued)

 

OMTT:

OMTT applies the provisions set forth in FASB ASC Topic 740, to account for uncertainty in income taxes.

Deferred income taxes result from the tax effect of transactions that are recognized in different periods for financial statement and income tax reporting purposes. OMTT’s net deferred income tax assets at December 31, 2015, were approximately $103,200, and have been fully offset by a valuation allowance, as their realization is not reasonably assured. These deferred income tax assets consist primarily of net operating losses and income tax credits, which may be carried forward to offset future income tax liabilities. OMTT has federal net operating loss carryforwards of $507,302 at December 31, 2015, which begin to expire in 2019. OMTT has no state net operating loss carryforwards at December 31, 2015. Additionally, OMTT has federal and state research and development income tax credits totaling $5,237 and $5,403, respectively, at December 31, 2015. The federal income tax credits may be carried forward until 2033. The state income tax credits may be carried forward indefinitely.

Under certain 1986 Tax Reform Act provisions, the availability of OMTT’s net operating loss and income tax credit carryforwards are subject to limitation if it should be determined, there has been a change in the ownership of more than 50% of the value of the Company’s capital stock. Such a determination could substantially limit the eventual utilization of these tax carryforwards.

OMTT uses the “more likely than not” criterion for recognizing the tax benefit of uncertain tax positions and establishing measurement criteria for income tax benefits. OMTT has evaluated the impact of its tax positions and believes that all income tax filing positions and deductions will be sustained upon examination and, accordingly, has not recorded any reserves or related accruals for interest and penalties for uncertain income tax positions as of December 31, 2015. In the event OMTT should need to recognize interest and penalties related to unrecognized tax liabilities, this amount will be recorded as an accrued liability and an increase to income tax expense.

OMTT files income tax returns in the U.S. federal jurisdiction and the state of California. Management believes OMTT is no longer subject to income tax examinations by taxing authorities for income tax filings prior to 2012 for federal and 2011 for state tax returns

 

- 19 -


Open Monoclonal Technology, Inc.,

OMT Therapeutics, Inc. and OMT, LLC

Notes to Combined Financial Statements

 

 

6.

Income Taxes (continued)

 

OMT, LLC:

Income taxes on OMT, LLC’s profit are the responsibility of the individual members; accordingly, no provision for income taxes is included in the accompanying combined financial statements. Members’ capital reflected in the accompanying combined financial statements does not necessarily represent the members’ income tax basis on their respective interests.

 

7.

Stockholders’ Equity

Common Stock:

OMTI is authorized to issue 25,000,000 shares of common stock with a par value of $0.001 per share. At December 31, 2015, 5,257,342 shares of common stock were issued and outstanding.

During 2015, OMTI has allowed certain option holders to exercise unvested options to purchase 123,750 shares of common stock. Shares received from such early exercises are subject to a right of repurchase at the issuance price. OMTI’s repurchase right with respect to these shares lapses over the same period the options vest. At December 31, 2015, 166,023 shares of common stock were subject to repurchase at a weighted-average price of $0.67 per share. Cash proceeds received for unvested shares of common stock of $101,000 was recorded within accrued expenses and other current liabilities. The amount of prior year early exercised options that vested during 2015 was $28,109. At December 31, 2015, the amount included in accrued expenses and other current liabilities related to unvested options was $111,000.

OMTT is authorized to issue 9,932,492 shares of common stock with a par value of $0.0001 per share. At December 31, 2015, 9,329,114 shares of common stock were issued and outstanding.

Convertible Preferred Stock:

OMTI is authorized to issue 10,063,000 shares of convertible preferred stock with a par value of $0.001 per share. The Board of Directors has designated 4,363,000 shares as Series A convertible preferred stock (Series A) and 5,700,000 shares as Series B convertible preferred stock (Series B). At December 31, 2015, OMTI has 4,362,599 shares of Series A and 4,590,149 shares of Series B issued and outstanding, respectively.

 

- 20 -


Open Monoclonal Technology, Inc.,

OMT Therapeutics, Inc. and OMT, LLC

Notes to Combined Financial Statements

 

 

7.

Stockholders’ Equity (continued)

 

Convertible Preferred Stock:

The holders of Series A and Series B (collectively, convertible preferred stock) have the rights, preferences, privileges and restrictions as set forth below:

Dividends:

The holders of convertible preferred stock are entitled to receive non-cumulative dividends prior to and in preference to any declaration or payment of dividends on common stock, when and if declared by the Board of Directors, at the rate of $0.17 per share for Series A and $0.09 per share for Series B, as adjusted for stock splits, dividends, reclassifications or the like, per annum. After payment of the above dividends to holders of convertible preferred stock, any additional dividends will be distributed pro rata amongst the holders of convertible preferred stock and common stock, on an as-if converted to common stock basis. No dividends have been declared or paid as of December 31, 2015.

Conversion:

Each share of convertible preferred stock is convertible to common stock, at the option of the holder, at any time after the date of issuance. Each share of convertible preferred stock automatically converts into the number of shares of common stock determined in accordance with the conversion rate upon the earlier of (i) the closing of a public offering, in which the aggregate proceeds exceed $30,000,000 and the price per share of common stock is not less than $5.45 or (ii) the written consent of the majority of holders of the then outstanding shares of convertible preferred stock, voting together as a single class. At December 31, 2015, the conversion price for Series A and Series B is $1.070217.

Liquidation Preferences:

In the event of any liquidation, dissolution or winding up of OMTI, whether voluntary or involuntary, the holders of shares of Series A and Series B are entitled to receive, prior to and in preference to the holders of common stock, an amount per share as adjusted for stock splits, dividends, reclassifications or the like equal to $0.00 and $0.6603 per share, plus all declared and unpaid dividends. If upon occurrence of such an event, the assets and funds to be distributed among the holders of Series A and Series B are insufficient to permit the payment to such holders, then the entire assets and funds of OMTI legally available for distribution will be distributed ratably among the holders of Series A and Series B in proportion to the preferential amount each such holder is otherwise entitled to receive.

 

- 21 -


Open Monoclonal Technology, Inc.,

OMT Therapeutics, Inc. and OMT, LLC

Notes to Combined Financial Statements

 

 

7.

Stockholders’ Equity (continued)

 

Convertible Preferred Stock: (continued)

 

Liquidation Preferences: (continued)

 

Upon completion of distributions noted above, the holders of Series A will be entitled to receive an amount per share equal to $1.09, the holders of Series B will be entitled to receive an amount per share equal to $1.09 and the holders of common stock will be entitled to receive an amount per share equal to $1.070217. If upon occurrence of such an event, the assets and funds to be distributed among the holders of Series A, Series B and common stock are insufficient to permit the payment to such holders, then the entire assets and funds of OMTI legally available for distribution will be distributed ratably among the holders of Series A, Series B and common stock in proportion to the preferential amount each such holder is otherwise entitled to receive.

Upon completion of distributions noted above, the holders of Series A will be entitled to receive an amount per share equal to $1.02 and the holders of common stock will be entitled to receive an amount per share equal to $1.001488. If upon occurrence of such an event, the assets and funds to be distributed among the holders of Series A and common stock are insufficient to permit the payment to such holders, then the entire assets and funds of OMTI legally available for distribution will be distributed ratably among the holders of Series A and common stock in proportion to the preferential amount each such holder is otherwise entitled to receive.

Upon completion of distributions noted above, the holders of common stock will be entitled to receive an amount per share equal to $0.068730. Upon completion of such distributions to common stock, the holders of Series B will be entitle to receive an amount per share equal to $2.04 and the holders of common stock will be entitled to receive an amount per share equal to $2.002975. If upon occurrence of such an event, the assets and funds to be distributed among the holders of Series B and common stock are insufficient to permit the payment to such holders, then the entire assets and funds of OMTI legally available for distribution will be distributed ratably among the holders of Series B and common stock in proportion to the preferential amount each such holder is otherwise entitled to receive.

Upon completion of distributions noted above, the remaining proceeds will be paid or distributed among the holder of Series A, Series B and common stock pro rata based on the number of shares of common stock held by each on an as converted basis.

 

- 22 -


Open Monoclonal Technology, Inc.,

OMT Therapeutics, Inc. and OMT, LLC

Notes to Combined Financial Statements

 

 

7.

Stockholders’ Equity (continued)

 

Convertible Preferred Stock: (continued)

 

Voting Rights:

The holders of each share of convertible preferred stock are entitled to voting rights equal to the number of shares of common stock into which the shares could be converted. The holders of Series A and Series B, voting as a single class and not as a separate series on an as-converted basis, are each entitled to elect two members of the OMTI’s Board of Directors. The holders of common stock, voting as separate class, are each entitled to elect two members of OMTI’s Board of Directors. The holders of a majority of the then outstanding shares of common stock, voting separately and a majority of the then outstanding shares of convertible preferred stock, voting together as a single class and not as a separate series on an as-converted basis, are entitled to elect any remaining members of the Board of Directors.

Protective Provisions:

The holders of convertible preferred stock have certain protective provisions. As long as at least 3,500,000 shares of convertible preferred stock are outstanding, OMTI cannot, without the approval of at least a majority of the then outstanding shares of convertible preferred stock, voting as a single class on an as-converted basis, take any actions, including but not limited to: (i) authorizes or issues a new class of preferred stock, or a consolidation, reclassification or split of convertible preferred stock; (ii) authorizes additional shares of convertible preferred stock; (iii) adversely alters, waives or affects the rights, preferences, privileges, powers of, or restrictions of convertible preferred stock; (iv) effect a liquidation event; or (v) change the authorized number of directors constituting the Board of Directors.

Redemption:

Shares of convertible preferred stock are not redeemable at the option of the holder at any time.

 

- 23 -


Open Monoclonal Technology, Inc.,

OMT Therapeutics, Inc. and OMT, LLC

Notes to Combined Financial Statements

 

 

7.

Stockholders’ Equity (continued)

 

Convertible Preferred Stock: (continued)

 

OMTT is authorized to issue 50,000 shares of convertible preferred stock with a par value of $0.0001 per share, which the Board of Directors has designated as Series 1 convertible preferred stock (Series 1). At December 31, 2015, OMTT has 50,000 shares of Series 1 issued and outstanding.

The holders of Series 1 have the rights, preferences, privileges and restrictions as set forth below:

Dividends:

The holders of Series 1 and common stock are entitled to receive non-cumulative dividends, when and if declared by the Board of Directors. Any such dividends will be distributed pro rata amongst the holders of Series 1 and common stock, on an as-if converted to common stock basis. No dividends have been declared or paid as of December 31, 2015.

Conversion:

Each share of Series 1 is convertible to common stock, at the option of the holder, at any time after the date of issuance. Each share of convertible preferred stock automatically converts into the number of shares of common stock determined in accordance with the conversion rate upon the earlier of (i) the closing of a public offering, in which the aggregate proceeds exceed $20,000,000 or (ii) the written consent of the majority of holders of the then outstanding shares of Series 1, voting together as a single class on an as-converted basis. At December 31, 2015, the conversion price for Series 1 is $12.87051.

Liquidation Preferences:

In the event of any liquidation, dissolution or winding up of OMTT, whether voluntary or involuntary, the holders of shares of Series 1 are entitled to receive, prior to and in preference to the holders of common stock, an amount per share as adjusted for stock splits, dividends, reclassifications or the like equal to $18.20 per share, plus all declared and unpaid dividends. If upon occurrence of such an event, the assets and funds to be distributed among the holders of Series 1 are insufficient to permit the payment to such holders, then the entire assets and funds of OMTT legally available for distribution will be distributed ratably among the holders of Series 1 in proportion to the preferential amount each such holder is otherwise entitled to receive.

 

- 24 -


Open Monoclonal Technology, Inc.,

OMT Therapeutics, Inc. and OMT, LLC

Notes to Combined Financial Statements

 

 

7.

Stockholders’ Equity (continued)

 

Convertible Preferred Stock: (continued)

 

Liquidation Preferences: (continued)

 

Upon completion of distributions noted above, the remaining proceeds will be paid or distributed among the holder of common stock pro rata based on the number of shares of common stock held by each.

Voting Rights:

The holders of each share of Series 1 are entitled to voting rights equal to the number of shares of common stock into which the shares could be converted. The holders of common stock, voting as separate class, are each entitled to elect four members of OMTT’s Board of Directors. The holders of outstanding Series 1 and common stock, voting together as a single class and not as a separate series on an as-converted basis, are entitled to elect any remaining members of the Board of Directors.

Protective Provisions:

The holders of Series 1 have certain protective provisions. As long as a majority of the Series 1 originally issued remain outstanding, OMTT cannot, without the approval of at least a majority of the then outstanding shares of Series 1, on an as-converted basis, take any actions, including: (i) increase or decrease, other than by conversion, the total number of authorized shares of Series 1 and (ii) adversely alters, waives or affects the rights, preferences, privileges, powers of, or restrictions of Series 1.

Redemption:

Shares of convertible preferred stock are not redeemable at the option of the holder at any time.

 

- 25 -


Open Monoclonal Technology, Inc.,

OMT Therapeutics, Inc. and OMT, LLC

Notes to Combined Financial Statements

 

 

7.

Stockholders’ Equity (continued)

 

Members’ Equity:

OMT, LLC is authorized to issue 4,711,959 common units. The Board of Managers has designated 126,894 of these common units as profit interest units. All common units and profit interest units are issued and outstanding at December 31, 2015.

OMT, LLC is authorized to issue 4,562,599 shares of preferred units. The Board of Managers has designated 200,000 units as Series A preferred units and 4,362,599 units as Series B preferred units, all of which is issued and outstanding at December 31, 2015.

The rights, preferences, privileges and restrictions of the Series A and Series B preferred units (collectively, preferred units) are as defined below:

Voting:

All common units and preferred units are each entitled to one vote, voting together as a single class.

Allocation of Net Income (Loss):

Net income and loss for any fiscal year will be allocated in such a manner as to cause a members capital account balance, as adjusted for all contributions, distributions and special allocations and increased by a members share of the OMT, LLC’s minimum gain attributable to nonrecourse debt of OMT, LLC, to equal each members respective amount that would be distributable to such member on such date if:

 

  (a)

All the assets of OMT, LLC (including intangible assets) were sold for cash equal to their respective book values as of such date;

 

  (b)

All liabilities of OMT, LLC were paid in full (except that in the case of a nonrecourse liability, such payment would be limited to the book value of the asset or assets securing such liability); and

 

  (c)

Each member were to pay OMT, LLC the amount of any obligation then unconditionally due.

 

- 26 -


Open Monoclonal Technology, Inc.,

OMT Therapeutics, Inc. and OMT, LLC

Notes to Combined Financial Statements

 

 

7.

Stockholders’ Equity (continued)

 

Members’ Equity: (continued)

 

Liquidation Preference:

The liquidation preference shall mean $50.00 per unit for each Series A preferred unit and $2.11 per unit for each Series B preferred unit, subject to adjustment if any distribution is received from OMTI.

Distributions:

The LLC Agreement provides for discretionary cash and in-kind property distributions during the term of the agreement. The Board of Managers of OMT, LLC may direct distributions derived from cash from operations or capital transactions to be made in the following order:

 

  (a)

First, to the Series A members, until an amount equal to the liquidation preference for each Series A preferred unit has been distributed;

 

  (b)

Second, to the Series B members, pro rata in proportion to the number of Series B preferred units held by each, until an amount equal to the liquidation preference for such Series B preferred units has been distributed;

 

  (c)

Third, to the common members, pro rata in proportion to the number of common units held by each, until an amount equal to the amount per unit distributed with respect to each Series B preferred unit has been distributed;

 

  (d)

Thereafter, to the Series B members and the common members, pro rata in proportion to the number of units held by each.

Distributions upon the final liquidation of OMT, LLC will be directed in the same order as detailed above, after payment of third-party debts and liabilities, and expenses of liquidation, excluding member-related indebtedness.

In July 2015, OMT, LLC received $4,350,000 from escrow from the sale of OMT 3, Inc. that occurred in 2013. This amount was distributed as follows: $56,378 to pay legal fees, $508,219 to repay outstanding debt due to OMTI and $3,785,393 to members.

 

- 27 -


Open Monoclonal Technology, Inc.,

OMT Therapeutics, Inc. and OMT, LLC

Notes to Combined Financial Statements

 

 

7.

Stockholders’ Equity (continued)

 

Warrants:

In connection with the issuance of a loan and security agreement entered into in May 2010, OMTI issued warrants to purchase a total of 85,308 shares of Series A. The warrant was automatically converted to purchase Series B, as defined per the agreement, upon Series B financing in March 2011 to purchase a total of 165,138 shares of Series B. The fair value of the warrants to purchase Series B of $133,112 was calculated using the Black-Scholes option pricing model and recorded as a preferred stock warrant liability. The liability was valued using the following assumptions: expected life of 9.15 years, fair value of Series B of $1.09 per share, risk-free interest rate of 3.42%, volatility of 72% and no expected dividends. The liability is subject to revaluation to fair value at the end of each reporting period until the earlier of the exercise or expiration of the warrants. At December 31, 2015, the change in fair value was $8,967 and is recorded in other income and expenses on the combined financial statements.

In connection with the Series B financing in March 2011, OMTI issued warrants to purchase a total of 458,716 shares of Series B. At time of grant, fifty percent of the warrant amount is exercisable with the remaining amount exercisable upon consummation of the second tranche of Series B. The ability to draw the second tranche of Series B expired December 31, 2012. At December 31, 2015, 226,366 warrants granted in conjunction with Series B financing remain outstanding. The fair value of the warrants of $172,959 was calculated using the Black-Scholes option pricing model and recorded as a preferred stock warrant liability. The liability was valued using the following assumptions: expected life of seven years, fair value of Series B of $1.09 per share, risk-free interest rate of 2.82%, volatility of 72% and no expected dividends. The liability is subject to revaluation to fair value at the end of each reporting period until the earlier of the exercise or expiration of the warrants. At December 31, 2015, the change in fair value was $20,282 and is recorded in other income and expenses on the combined financial statements.

In connection with the issuance of a loan and security agreement entered into in April 2012, OMTI issued warrants to purchase a total of 229,358 shares of Series B. The fair value of the warrants of $203,135 was calculated using the Black-Scholes option pricing model and recorded as a preferred stock warrant liability. The liability was valued using the following assumptions: expected life of 10 years, fair value of Series B of $1.09 per share, risk-free interest rate of 2.00%, volatility of 80.1% and no expected dividends. The liability is subject to revaluation to fair value at the end of each reporting period until the earlier of the exercise or expiration of the warrants. At December 31, 2015, the change in fair value was $8,647 and is recorded in other income and expenses on the combined financial statements.

 

- 28 -


Open Monoclonal Technology, Inc.,

OMT Therapeutics, Inc. and OMT, LLC

Notes to Combined Financial Statements

 

 

7.

Stockholders’ Equity (continued)

 

Warrants: (continued)

 

In connection with the issuance of convertible notes payable in May 2013, OMTI issued warrants to purchase 183,486 shares of convertible preferred stock of OMTI or any of their affiliates. The convertible note was paid back in full in June 2015. The fair value of the warrants of $180,780 was calculated using the Black-Scholes option pricing model and recorded as a preferred stock warrant liability. The liability was valued using the following assumptions: expected life of seven years, fair value of Series B of $1.09 per share, risk-free interest rate of 1.25%, volatility of 80.1% and no expected dividends. The liability is subject to revaluation to fair value at the end of each reporting period until the earlier of the exercise or expiration of the warrants. At December 31, 2015, the change in fair value was $9,908 and is recorded in other income and expenses on the combined financial statements.

 

8.

Stock Option Plans

OMTI Stock Plan:

In September 2007, OMTI approved the Open Monoclonal Technology, Inc. 2007 Stock Plan (the OMTI Plan) under which 1,875,472 shares of OMTI’s common stock has been reserved for issuance to employees, directors, non-employee directors and consultants.

Under the OMTI Plan, OMTI is authorized to issue incentive stock options (ISO) and non-statutory stock options (NSO). ISOs may only be granted to OMTI employees. NSOs may be granted to OMTI employees, directors and consultants. The Plan provides for stock option grants at an exercise price no less than 100% of the fair value of the common stock subject to the option on the date of grant, or 110% in the case of options granted to owners of 10% or more of OMTI’s capital stock. Fair value is determined by the Board of Directors based on an independent valuation. Options expire after 10 years (five years for stockholders owning greater than 10% of the voting stock). The Board of Directors determines the period over which the options vest and become exercisable.

In 2015, OMTI recognized $120,000 of stock-based compensation related to options granted to employees. Compensation expense for non-employees was not significant in 2015. The compensation expense is allocated on a departmental basis, based on the classification of the option holder. No income tax benefits have been recognized in the combined statement of operations for stock-based compensation arrangements and no stock-based compensation costs have been capitalized as of December 31, 2015.

 

- 29 -


Open Monoclonal Technology, Inc.,

OMT Therapeutics, Inc. and OMT, LLC

Notes to Combined Financial Statements

 

 

8.

Stock Option Plans (continued)

 

OMTI Stock Plan: (continued)

 

The fair value of each award to employees is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions in 2015: expected life of 6.02 to 6.08 years, risk-free interest rate of 1.72%, expected volatility of 84.3% and no dividends during the expected life. Expected volatility is based on historical volatilities of public companies operating in OMTI’s industry. The expected life of the options represents the period of time options are expected to be outstanding and is estimated considering vesting terms. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant.

Future stock based compensation for unvested employee options granted and outstanding as of December 31, 2015 is $195,000 to be recognized over a remaining requisite service period of 2.59 years.

Stock option activity under the OMTI Plan is as follows:

 

           Options Outstanding  
                       
    

Options
    Available    

   

Number
    of Shares    

   

Weighted-
Average
 Exercise Price 

 

Balances, December 31, 2014

     15,242        671,383      $ 0.25   

Increase in authorized shares

     435,000        -        -   

Options granted

     (435,000     435,000        0.80   

Exercised

     -        (275,000     0.58   
  

 

 

   

 

 

   

 

 

 

Balances, December 31, 2015

     15,242        831,383      $ 0.43   
  

 

 

   

 

 

   

 

 

 

At December 31, 2015, there were 989,868 employee shares vested with a weighted-average exercise price of $0.33 per share and a weighted-average remaining contractual life of 6.80 years.

OMTT Stock Plan:

In January 2012, OMTT adopted the OMT Therapeutics, Inc. 2011 Stock Plan (the OMTT Plan) and also adopted the UK addendum under the OMTT Plan to allow certain employees and full-time directors based in the United Kingdom to receive enterprise management incentive options (the EMI Plan). Under the OMTT Plan and the EMI Plan, OMTT has reserved 1,000,000 shares of OMTT’s common stock for issuance to employees, directors, non-employee directors and consultants. The EMI Plan is governed by the terms of the OMTT Plan (collectively, the OMTT Plan).

 

- 30 -


Open Monoclonal Technology, Inc.,

OMT Therapeutics, Inc. and OMT, LLC

Notes to Combined Financial Statements

 

 

8.

Stock Option Plans (continued)

 

OMTI Stock Plan: (continued)

 

Under the OMTT Plan, OMTT is authorized to issue incentive stock options (ISO) and non-statutory stock options (NSO). ISOs may only be granted to OMTT employees. NSOs may be granted to OMTT employees, directors and consultants. Under the EMI Plan, OMTT is authorized to issue enterprise management incentive options. The OMTT Plan provides for stock option grants at an exercise price no less than 100% of the fair value of the common stock subject to the option on the date of grant, or 110% in the case of options granted to owners of 10% or more of OMTT’s capital stock. Fair value is determined by the Board of Directors based on an independent valuation. Options expire after 10 years (five years for stockholders owning greater than 10% of the voting stock). The Board of Directors determines the period over which the options vest and become exercisable.

In 2015, OMTT recognized $6,000 of stock-based compensation related to options granted to employees. Compensation expense for non-employees was not significant in 2015. The compensation expense is allocated on a departmental basis, based on the classification of the option holder. No income tax benefits have been recognized in the combined statement of operations for stock-based compensation arrangements and no stock-based compensation costs have been capitalized as of December 31, 2015.

There were no awards granted to employees in 2015. All options are fully vested at December 31, 2015 and as such, no future stock-based compensation for unvested options granted and outstanding as of December 31, 2015.

Stock option activity under the OMTT Plan is as follows:

 

            Options Outstanding  
                        
     Shares
    Available    
     Number
    of Shares    
        Weighted -   
Average
Exercise
Price
 

Balances, December 31, 2014

     156,385         843,615      $ 0.06   

Exercised

     -         (446,622     0.06   
  

 

 

    

 

 

   

 

 

 

Balances, December 31, 2015

     156,385         396,993      $ $.06   
  

 

 

    

 

 

   

 

 

 

At December 31, 2015, 396,993 options were vested and exercisable with a weighted-average exercise price of $0.06 and weighted-average remaining contractual life of 6.09 years.

 

- 31 -


Open Monoclonal Technology, Inc.,

OMT Therapeutics, Inc. and OMT, LLC

Notes to Combined Financial Statements

 

 

9.

Commitments and Contingencies

Facility Leases:

OMTT leases an office facility in Menlo Park, California on a month-to-month basis which ended in January 2016. In November 2015, OMTT entered into a new non-cancellable operating lease agreement for office facilities in Menlo Park, California which begins in February 2016 and expires in February 2021. Additionally, OMTT leases office facilities in Cambridge, United Kingdom under a non-cancelable operating lease agreement which expires in September 2016. Under the terms of the leases, OMTT is responsible for certain insurance, property tax and maintenance expenses. OMTT recognized rent expense on a straight-line basis. Rent expense for OMTT’s facilities was $151,631 in 2015.

Future minimum lease payments are as follows:

 

Years ending December 31:

  

2016

   $           258,000   

2017

     269,000   

2018

     276,000   

2019

     284,000   

2020

     293,000   

Thereafter

     49,000   
  

 

 

 
   $ 1,429,000   
  

 

 

 

Indemnification

The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these arrangements is not determinable. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company believes the estimated fair value of these agreements is minimal. The Company had entered into indemnification agreements with its directors, officers, employees and other agents of the Company that many required the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or services as directors of officers other than liabilities arising from willful misconduct of the individual.

 

- 32 -


Open Monoclonal Technology, Inc.,

OMT Therapeutics, Inc. and OMT, LLC

Notes to Combined Financial Statements

 

 

10.

Employee Benefit Plans

OMTI and OMTT have 401(k) plans under which employees may contribute a portion of their compensation to the plans, subject to the limitations under the Internal Revenue Code. OMTI and OMTT’s contributions to the plans are at the discretion of the Board of Directors. Neither company has made any contributions to the plans, other than the 4% Safe Harbor contributions (subject to the limitations under the Internal Revenue Code) through December 31, 2015.

 

11.

Combination of Variable Interest Entities

OMTI provides on-going financial support to OMTT and OMT, LLC. OMTI was deemed the primary beneficiary of these entities in 2015 and 2014, even though it has no ownership interest in them because OMTI has the power to direct activities that significantly impact their economic performance and the obligation to absorb losses.

The following table summarizes the balance sheets for our combined VIE’s as of December 31, 2015:

 

       OMT, LLC             OMTT           Total  

Assets:

              

Cash and cash equivalents

   $ 10          $       1,139,020          $       1,139,030   

Other assets

             23,930            437,377            461,307   

Property and equipment, net

     -            509,437            509,437   
  

 

 

       

 

 

       

 

 

 

Total assets

   $ 23,940          $ 2,085,834          $ 2,109,774   
  

 

 

       

 

 

       

 

 

 

Liabilities:

              

Accounts payable

   $ -          $ 159,894          $ 159,894   

Accrued expenses

     -            37,025            37,025   

Stockholders’ equity

     23,940            1,888,915            1,912,855   
  

 

 

       

 

 

       

 

 

 

Total liabilities and stockholders equity

   $ 23,940          $ 2,085,834          $ 2,109,774   
  

 

 

       

 

 

       

 

 

 

 

- 33 -


Open Monoclonal Technology, Inc.,

OMT Therapeutics, Inc. and OMT, LLC

Notes to Combined Financial Statements

 

 

12.

Subsequent Events

On March 3, 2016, OMTT amended its Articles of Incorporation to change the name of OMTT to TENEObio, Inc.

In March 2016, OMTT issued convertible security agreements to existing shareholders totaling $4,318,000. The security agreements are convertible into the next round of OMTT’s equity financing.

Subsequent events have been evaluated through the date of the independent auditors’ report, which is the date the combined financial statements were approved by the Company and available to be issued. Except for the acquisition of OMTI and OMT, LLC by Ligand Pharmaceuticals, Inc., no other subsequent events were identified requiring disclosure.

 

- 34 -

Exhibit 99.2

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

On January 8, 2016, Ligand Pharmaceuticals Incorporated (the “Company”, “Ligand”, “we” or “us”) completed the acquisition of substantially all of the assets and liabilities of Open Monoclonal Technology, Inc. (“OMT, Inc.”) and its wholly owned subsidiaries (together “OMT”) pursuant to the terms and conditions of the Agreement and Plan of Merger, dated as of December 17, 2015 (the “Merger Agreement”).

The unaudited pro forma condensed combined financial information is presented in accordance with the rules specified by Article 11 of Regulation S-X promulgated by the Securities and Exchange Commission (the “SEC”) and has been prepared subject to the assumptions and adjustments as described in the notes thereto.

The following unaudited pro forma condensed combined statement of financial condition as of December 31, 2015 gives effect to the acquisition of substantially all of the assets of OMT as if it had occurred on December 31, 2015, and the following unaudited pro forma condensed combined statement of operations for the year ended December 31, 2015 gives effect to the acquisition as if it had occurred as of January 1, 2015, subject to the assumptions and adjustments as described in the accompanying notes. The adjustments included in the column “Assets and Liabilities Not Acquired” in the unaudited pro forma condensed combined statement of financial condition and statements of operations represent the assets that were not acquired and liabilities that were not assumed in connection with the OMT acquisition, and also the corresponding revenues and expenses. The historical financial information is adjusted in the unaudited pro forma financial statements to give effect to pro forma adjustments that are (1) directly attributable to the acquisition, (2) factually supportable, and (3) with respect to the pro forma statements of operations, expected to have a continuing impact on the combined results.

The unaudited pro forma condensed combined financial information is presented for informational purposes only and is not necessarily indicative of the financial condition or results of operations that would have occurred if the acquisition had been consummated on the dates indicated, nor is it indicative of the future financial condition or results of operations of the combined company. The unaudited pro forma condensed combined financial information does not give effect to any potential cost savings or other operational efficiencies that could result from the acquisition.

The pro forma combined condensed financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2015 and notes thereto of Ligand contained in its 2015 Annual Report on Form 10-K, filed with the Securities and Exchange Commission on February 26, 2016 and the historical audited financial statements for the year ended December 31, 2015 and notes thereto of OMT which are included as Exhibit 99.1 to this Current Report on Form 8-K/A.

The Company has made a preliminary estimated allocation of the consideration transferred to the assets acquired and liabilities assumed as of the acquisition date based on the preliminary information available and management’s preliminary valuation of the fair value of tangible and intangible assets acquired and liabilities assumed. The finalization of the Company’s purchase accounting assessment may result in changes to the valuation of assets acquired and liabilities assumed, particularly in regards to indefinite and finite-lived intangible assets and deferred tax assets and liabilities, which could be material. Accordingly, the pro forma adjustments related to the allocation of estimated consideration transferred are preliminary and have been presented solely for the purpose of providing unaudited pro forma condensed combined financial information in this Current Report on Form 8-K/A. The Company expects to finalize its accounting for the business combination as soon as practicable within the measurement period in accordance with Accounting Standards Codification Topic 805 “Business Combinations” (“ASC 805”), but in no event later than one year from January 8, 2016 (the “Acquisition Date”).

 

1


UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF FINANCIAL CONDITION

As of December 31, 2015

(in thousands)

 

  

 

 

    

 

 

         

 

 

 
     Ligand      OMT                     Pro Forma Combined    
       As of December 31,          As of December 31,          Assets and Liabilities        Pro forma       As of December 31,    
     2015      2015      not acquired1        adjustments       2015  
             

Assets

             

Cash and cash equivalents

     $ 97,428           $ 4,638           $ (1,139)          $ (96,423)    A      $ 4,504     

Short-term investments

     102,791           -               -               -              102,791     

Accounts receivable, net

     6,170           2           -               -              6,172     

Note receivable from Viking

     4,782           -               -               -              4,782     

Inventory

     1,633           -               -               -              1,633     

Current debt issuance costs

     860           -               -               -              860     

Other current assets

     1,908           517           (347)          1,250     B      3,328     
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

Total current assets

     215,572           5,157           (1,486)          (95,173)         124,070     

Deferred income taxes

     216,564           3,147           -               766     C      220,477     

Investments in equity securities

     29,728           -               -               -              29,728     

Intangible assets, net

     48,347           214           (23)          166,809     F      215,347     

Goodwill

     12,238           -               -               63,722     H      75,960     

Commercial license rights

     8,554           -               -               -              8,554     

Property and equipment, net

     372           509           (509)          -              372     

Long-term debt issuance costs

     2,527           -               -               -              2,527     

Other assets

     27           68           -               -              95     
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

Total assets

     $ 533,929           $ 9,095           $ (2,018)          $ 136,124          $ 677,130     

LIABILITIES AND SHAREHOLDERS’ EQUITY

             

Current liabilities:

             

Accounts payable

     $ 4,083           $ 998           $ (160)          $ -          $ 4,921     

Accured liabilities

     5,397           148           (37)          388     I      5,896     

Current contingent liabilities

     10,414           -               -               -              10,414     

Current lease exit obligations

     934           -               -               -              934     

Other current liabilities

     8           1,979           -               (1,979)    G      8     
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

Total current liabilities

     20,836           3,125           (197)          (1,591)         22,173     

Long-term liabilities:

             

Long-term portion of notes payable

     205,372           -               -               -              205,372     

Long-term contingent liabilities

     3,033           -               -               -              3,033     

Long-term deferred income taxes

     -               -               -               64,546     C      64,546     

Other long-term liabilities

     297           545           -               -              842     
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

Total liabilities

     $ 229,538           $ 3,670           $ (197)          $ 62,955          $ 295,966     

Shareholders’ equity:

             

Common stock

     $ 20           $ 5           $ -               $ (5)    D      $ 20     

Convertible Preferred Stock

     -               9           -               (9)    D      -         

Additional paid-in capital

     701,478           9,405           (62)          68,304     D, E      779,125     

Accumulated other comprehensive income

     4,903           -               (1,759)          23          3,167     

Accumulated deficit

     (402,010)          (3,994)          -               4,856     B,D, I      (401,148)    
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

Total stockholders’ equity attributable to parent

     304,391           5,425           (1,821)          73,169          381,164     
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

Noncontrolling interests

     -               -               -               -              -         
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

Total stockholders’ equity

     304,391           5,425           (1,821)          73,169          381,164     
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

Total liabilities and stockholders’ equity

     $ 533,929           $ 9,095           $ (2,018)          $ 136,124          $ 677,130     
  

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

 

  1

The Merger Agreement excludes OMT Therapeutics Inc. (“OMTT”) and its wholly owned subsidiary reported within OMT’s 2015 financial statements. For purposes of the Unaudited Pro Forma Condensed Combined Financial Statements, these assets, liabilities and any income statement activity related to these legal entities have been excluded.

 

 

2


UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS

For the Year Ended December 31, 2015

(in thousands, except per share amounts)

 

    Historical     Historical                    
    Ligand     OMT                   Pro Forma Combined    
    Year Ended     Year Ended       Assets and Liabilities       Pro Forma     Year Ended  
      December 31, 2015        December 31, 2015      not acquired1         Adjustments             December 31, 2015      

Revenues

         

Royalties

    $ 38,194          $ -              $ -              $ -              $ 38,194     

Material Sales

    27,662          -              -              -              27,662     

License fees, milestones and other revenues

    6,058          7,525          (73)         -              13,510     
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total revenues

    71,914          7,525          (73)         -              79,366     
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Operating costs and expenses:

         

Cost of material sales

    5,807          -              -              -              5,807     

Cost of license revenue

    -              195          -              8,352     A      8,547     

Research and development

    13,380          6,094          (1,523)         2,543     C, B      20,494     

General and administrative

    24,378          3,916          (2,074)         (1,219)    A, B, E      25,001     

Lease exit and termination costs

    1,020          -              -              -              1,020     

Write-off of acquired in-process research and development

    -              -              -              -              -         
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total operating costs and expenses

    44,585          10,205          (3,597)         9,676          60,869     
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income from operations

    27,329          (2,680)         3,524          (9,676)         18,497     
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Other (expense) income:

         

Interest expense, net

    (11,802)         (258)         -              -              (12,060)    

Increase in contingent liabilities

    (5,013)         -              -              -              (5,013)    

Gain on deconsolidation of Viking

    28,190          -              -              -              28,190     

Equity in net losses from Viking

    (5,143)         -              -              -              (5,143)    

Other, net

    1,768          (1)         (34)         -              1,733     
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total other expense, net

    8,000          (259)         (34)         -              7,707     
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) from continuing operations before income tax

    35,329          (2,939)         3,490          (9,676)         26,204     

Income tax (expense) benefit from continuing operations

    219,596          1,274          (83)         4,210     D      224,997     
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) from continuing operations including noncontrolling interests

    254,925          (1,665)         3,407          (5,466)         251,201     
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Less: Net loss attributable to noncontrolling interests

    (2,380)         -              -              -              (2,380)    
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income (loss) from continuing operations

    $ 257,305          $ (1,665)         $ 3,407          $ (5,466)         $ 253,581     
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Basic per share amounts

         

Income (loss) from continuing operations

    $ 13.00                   F      $ 12.32     
 

 

 

         

 

 

 

Net income (loss)

    $ 13.00                   F      $ 12.32     
 

 

 

         

 

 

 

Weighted average number of common shares-basic

    19,790                20,584     
 

 

 

         

 

 

 

Diluted per share amounts:

         

Income (loss) from continuing operations

    $ 12.12                   F      $ 11.51     
 

 

 

         

 

 

 

Net income (loss)

    $ 12.12                   F      $ 11.51     
 

 

 

         

 

 

 

Weighted average number of common shares-diluted

    21,228                22,022     
 

 

 

         

 

 

 

 

  1

The Merger Agreement excludes OMT Therapeutics Inc. (“OMTT”) and its wholly owned subsidiary reported within OMT’s 2015 financial statements. For purposes of the Unaudited Pro Forma Condensed Combined Financial Statements, these assets, liabilities and any income statement activity related to these legal entities have been excluded.

 

3


NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

 

  1.

Description of Transaction and Basis of Presentation

On January 8, 2016, Ligand completed the acquisition of substantially all of the assets and liabilities of OMT pursuant to the terms and conditions of the Merger Agreement, by and among Ligand, OMT, Inc., OMT LLC, certain Ligand subsidiaries formed solely for the merger transactions, and Fortis Advisors LLC, as the stockholders’ representative, dated as of December 17, 2015. As a result, OMT, Inc. merged with and into Ligand with Ligand being the surviving corporation (the “Merger”). In addition, prior to the Merger, OMT, Inc. and OMT LLC entered into a stock exchange agreement pursuant to which all of OMT LLC’s subsidiaries became wholly-owned subsidiaries of OMT, Inc. by exchanging all outstanding shares of OMT LLC’s subsidiaries’ stock for shares of Class A Common Stock of OMT, Inc. Upon the completion of all the above mentioned transactions, OMT, including its subsidiaries, became a wholly-owned subsidiary of Ligand.

Ligand unaudited pro forma condensed combined financial information has been compiled from underlying financial statements prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) and in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and reflect the acquisition of substantially all of the assets of OMT.

The following unaudited pro forma condensed combined statement of financial condition as of December 31, 2015 gives effect to the acquisition of substantially all of the assets of OMT as if it had occurred on December 31, 2015, and the following unaudited pro forma condensed combined statement of operations for the year ended December 31, 2015 gives effect to the acquisition as if it had occurred as of January 1, 2015, subject to the assumptions and adjustments as described in the accompanying notes. The adjustments included in the column “Assets Not Acquired and Liabilities Not Assumed” in the unaudited pro forma condensed combined statement of financial condition and statements of operations represent the assets that were not acquired/liabilities not assumed in connection with the OMT acquisition, and also the corresponding revenues and expenses. The historical financial information is adjusted in the unaudited pro forma financial statements to give effect to pro forma adjustments that are (1) directly attributable to the acquisition, (2) factually supportable, and (3) with respect to the pro forma statements of operations, expected to have a continuing impact on the combined results.

The unaudited pro forma condensed combined financial statements for the year ended December 31, 2015 includes balances derived from the audited financial statements of OMT Therapeutics, Inc. (“OMTT”), an entity under common control with OMT, Inc, as of December 31, 2015, which was not a part of the entities acquired by Ligand or under common control with Ligand. These audited financial statements are attached as Exhibit 99.1 to this Current Report on Form 8-K/A. The use of audited financial statements of an entire consolidated entity where only selected parts of an entity are acquired and those acquired parts represent substantially all of the selling entity has been used in accordance with published SEC observations. The amounts which are attributable to this entity have been recorded as a pro forma adjustment to the unaudited pro forma condensed combined financial statements for the year ended December 31, 2015.

The following reclassification adjustments have been made to OMT’s historical financial statements to conform to Ligand’s presentation (in thousands):

 

4


       Historical OMT line  
items
     Reclassification
adjustment to
  conform to Ligand  
presentation
               Revised OMT          
historical
 

Balance sheet

        

As of December 31, 2015

        

(in thousands)

        

Other current assets

     $ -               $ 517           $ 517     

Income tax receivable

     379           (379)          -         

Prepaid expenses and other current assets

     138           (138)          -         

    

        

Deferred Income Tax Assets, non-current portion

     2,858           290           3,147     

Deferred income tax assets

     290           (290)          -         

    

        

Other Assets

     -               68           68     

Deposits

     68           (68)          -         

    

        

Accounts payable

     506           492           998     

Accrued expenses and other current liabilities

     640           (492)          148     

    

        

Other current liabilities

     -               1,979           1,979     

Deferred revenue

     1,979           (1,979)          -         

    

        

Other long-term liabilities

     -               545           545     

Preferred stock warrant liability

     545           (545)          -         

    

        

Convertible Preferred Stock

     -               9           9     

Series B, convertible preferred stock

     5           (5)          -         

Series A, convertible preferred stock

     4           (4)          -         

    

        

Income Statement

        

Year ended December 31, 2015

        

(in thousands)

        

License fees, milestones and other revenues

     $ -               $ 7,525           $ 7,525     

Revenues

     7,525           (7,525)          -         

    

        

Cost of license revenue

     -               195           195     

Cost of Revenue

     195           (195)          -         

    

        

General and administrative

     3,360           556           3,917     

Sales and marketing

     556           (556)          -         

    

        

Other, net

     -               (1)          (1)    

Gain on revaluation of warrants

     48           (48)          -         

Other income

     0           (0)          -         

Foreign currency translation loss

     $ (49)          $ 49           $ -         

 

5


 

  2.

Total Purchase Consideration and Preliminary Purchase Price Allocation

The acquisition of OMT has been accounted for using the acquisition method of accounting in accordance with ASC 805, which requires, among other things, that the assets acquired and liabilities assumed be recognized at their acquisition date fair values, with any excess of the consideration transferred over the estimated fair values of the identifiable net assets acquired recorded as goodwill.

The accounting for the business combination is based on currently available information and is considered preliminary. The final accounting for the business combination may differ materially from that presented in these unaudited pro forma condensed financial statements.

The consideration transferred to acquire OMT was approximately $174.1 million, consisting of approximately $96.4 million in cash and $77.7 million in shares of Ligand’s common stock, subject to certain customary post-closing adjustments, in each case upon the terms and subject to the conditions contained in the Merger Agreement. The following table summarizes the preliminary estimate of consideration expected to be transferred ($ in thousands):

 

Cash Consideration

     $ 96,423     

Fair value of Ligand’s common shares issued

     77,709     
  

 

 

 

Total fair value of consideration transferred

     $       174,132     
  

 

 

 

The following table presents the preliminary purchase price allocation of the assets acquired and liabilities assumed based on their estimated fair values as if the acquisition had occurred on December 31, 2015, which is the assumed acquisition date for purposes of the pro forma balance sheet (in thousands):

 

Net book value of assets acquired as of December 31, 2015

     $ 5,425     

    

  

Adjustments:

  

Identifiable Intangible Assets

     166,786     

Deferred revenue

     1,979     

Deferred taxes

     (63,780)    

Goodwill

     63,722     
  

 

 

 

Total net assets acquired

     $       174,132     
  

 

 

 

Ligand believes the amount of goodwill resulting from the allocation of purchase consideration is primarily attributable to OMT’s revenue growth from combining the OMT and Ligand businesses and workforce, as well as the benefits of access to different markets and customers.

 

  3.

Adjustments to Unaudited Pro Forma Condensed Combined Balance Sheet:

The following notes relate to the unaudited pro forma condensed combined balance sheet as of December 31, 2015:

 

  A.

Cash and cash equivalents To record the cash portion of purchase consideration paid by Ligand.

 

  B.

Intercompany transactions To reverse various previously eliminated intercompany transactions between OMT and OMTT, its wholly owned subsidiary, which was not acquired by Ligand in connection with the OMT acquisition.

 

  C.

Deferred tax assets and liabilities To record adjustments to deferred tax balances related to the change in fair values in connection with acquisition accounting and the recording of purchased intangible assets.

 

  D.

Equity—To eliminate OMT historical stockholder’s equity.

 

6


  E.

Common stock—To record the issuance of common stock as part of the consideration for the OMT acquisition.

 

  F.

Intangible Assets - To record the difference between the historical amounts of OMT net intangible assets and the preliminary fair values of OMT intangible asset acquired. These estimated fair value and useful life are considered preliminary and are subject to change based on final purchase price valuation amounts. Accordingly, the estimates related to deferred taxes are also subject to change. Changes in fair value or useful life of the acquired intangible asset may be material. The fair value of the core technologies was estimated based on an income approach using the multi-period excess earnings method. The remaining useful life of core technologies was estimated based on the related patent life and the expected future economic benefit of the asset and is being amortized over the estimated useful life in proportion to the economic benefits consumed using the straight-line method.

 

     Estimated      Estimated Fair           
     Average    Value         
       Useful Life        December 31,      Pro Forma  
(in thousands, except years)    (Years)    2015        Adjustment    

Core technologies

   20      167,000           166,786     

 

  G.

Deferred revenue— To eliminate the historical balance of OMT’s deferred revenue. Based on the preliminary purchase price allocation, it was determined that there was no remaining performance obligation related to the deferred revenue balance as of the Acquisition Date. No corresponding adjustments have been recorded in the unaudited pro forma condensed combined statement of operations as the impact is not expected to be recurring.

 

  H.

Goodwill—To record the preliminary estimate of goodwill for the acquisition of OMT.

 

  I.

Transaction Costs — To record an estimated accrual and accumulated deficit impact of $362,000 for transaction costs that have not been recognized in the historical financial statements.

 

  4.

Adjustments to Unaudited Pro Forma Condensed Statement of Operations:

 

  A.

Intangible amortization—To eliminate historical amortization expense related to OMT’s existing intangible assets and to reflect amortization of acquired intangible asset based on the preliminary estimated fair value and useful life expected to be recorded as a result of the merger. For the preliminary estimated fair value of the intangible asset and the associated useful life, see Note 3 (F).

 

     December, 31      
     2015      
     (in thousands)      

To eliminate the historical amortization expense of OMT from G&A

     $ (166)      

To record new amortization expense of OMT to cost of license revenue

                         8,352      
  

 

 

   

Total adjustments to amortization expense

     $ 8,186       
  

 

 

   

 

  B.

Stock-based compensation expense – To eliminate the historical stock-based compensation expense related to OMT’s existing equity awards and reflect the new stock-based compensation expense for 2015 related to the stock awards issued to the retained OMT employees.

 

     December, 31      
     2015      
     (in thousands)      

To eliminate the historical stock-based compensation of OMT from G&A

     $ (57)      

To record new stock-based compensation to R&D

                         1,000      

To record new stock-based compensation to G&A

     208      
  

 

 

   

Total adjustments to stock-based compensation expense

     $ 1,151       
  

 

 

   

 

  C.

Intercompany transactions To reverse various previously eliminated intercompany transactions between OMT and OMTT and its wholly owned subsidiary, which was not acquired by Ligand in connection with the OMT acquisition.

 

7


  D.

Income tax expense – This represents the tax effect of adjustments to income before income taxes, resulting in a blended tax rate benefit of 38.7% for the year end December 31, 2015, representing the estimated combined effective U.S. federal and state statutory rates. However, the effective tax rate of the combined company could be significantly different (either higher or lower) depending on post-acquisition activities.

 

  E.

Transaction costs—To eliminate transaction costs of approximately $1.2 million, as they are not expected to be recurring. To the extent that Ligand or OMT incur such costs in the future, they will be expensed in the statements of operations of the respective companies in the periods incurred.

 

  F.

The unaudited pro forma condensed combined basic and diluted earnings per share calculations are based on the combined basic and diluted weighted-average shares, after giving effect to the exchange ratio. The historical basic and diluted weighted average shares of OMT are assumed to be replaced by the shares issued by Ligand to effect the merger as follows:

 

     Year ended       
       December 31, 2015         
     (in thousands, except per
share amounts)
      

Pro Forma Weighted Average Shares (Basic)

     

Historical Ligand Weighted Average Shares Outstanding

     19,790        

Shares issued as consideration for OMT

     794        
  

 

 

    

Pro Forma Weighted Average Shares (Basic)

     20,584        

    

     

Pro Forma Weighted Average Shares (Diluted)

     

Pro Forma Weighted Average Shares (Basic)

     20,584        

Ligand Dilution (variance between diluted and basic)

     1,438        
  

 

 

    

Pro Forma Weighted Average Shares (Diluted)

     22,022        

    

     

Pro Forma Basic Earnings (Loss) Per Share

     

Pro Forma Income from Continuing Operations

     $ 253,581        

Basic Weighted Average Shares Outstanding

     20,584        
  

 

 

    

Pro Forma Basic Earnings (Loss) Per Share

     $ 12.32        

    

     

Pro Forma Diluted Earnings (Loss) Per Share

     

Pro Forma Income from Continuing Operations

     $                 253,581        

Diluted Weighted Average Shares Outstanding

     22,022        
  

 

 

    

Pro Forma Diluted Earnings (Loss) Per Share

     $ 11.51        

 

8



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings